Key Takeaways EXEL reported Q2 adjusted EPS of $0.75, beating estimates but down from $0.84 in the prior-year quarter.Revenues fell 10.8% year over year to $568.3M, missing estimates due to a sharp drop in collaboration income.Cabometyx sales rose 18.8% to $517.9M, with early NET indication demand accounting for 4% of total use.Exelixis, Inc. ((EXEL) reported mixed results for the second quarter of 2025.Adjusted earnings of 75 cents per share beat the Zacks Consensus Estimate of 65 cents. The company regist ...